🍀 Spring Appointment, Lucky Draw Gifts! Growth Value Issue 1️⃣7️⃣ Spring Lucky Draw Carnival Begins!
Seize Spring Luck! 👉 https://www.gate.com/activities/pointprize?now_period=17
🌟 How to Participate?
1️⃣ Enter [Plaza] personal homepage, click the points icon next to your avatar to enter [Community Center]
2️⃣ Complete plaza or hot chat tasks like posting, commenting, liking, and speaking to earn growth value
🎁 Every 300 points can draw once, 10g gold bars, Gate Red Bull gift boxes, VIP experience cards and more great prizes await you!
Details 👉 https://www.gate.com/announcements/article/
百健Hybrozyme交易将Subcutaneous Biologics的推动与估值差距联系起来
Biogen 已与 Alteogen 签署了一份独家许可协议,涉及其 Hybrozyme (ALT-B4) 技术,专注于开发两种生物药物的皮下版本,并有选择第三种的选项。此次合作旨在通过将生物药物转移到家庭皮下给药,提高患者的便利性和可及性。尽管 Biogen 的股票最近表现出积极的势头,年初至今上涨了 7.4%,但其估值被 Simply Wall St 模型认为大约低于其估计的公允价值 50.2%。